Steven M Devine

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
    Steven M Devine
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 112:990-8. 2008
  2. pmc Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network prot
    Steven M Devine
    Medicine Department of Ohio State University, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 17:1343-51. 2011
  3. pmc Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
    Mehdi Hamadani
    Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:547-53. 2009
  4. pmc Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009
  5. ncbi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
    Leuk Lymphoma 49:1893-8. 2008
  6. pmc Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma
    Neil C Dunavin
    Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Leuk Lymphoma 54:1658-64. 2013
  7. pmc Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 51:243-51. 2010
  8. doi request reprint High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Eur J Haematol 81:425-31. 2008
  9. pmc Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma
    Jarrod T Bruce
    Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Clin Lymphoma Myeloma Leuk 12:325-9. 2012
  10. pmc Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, B310 Starling Loving Hall, Columbus, OH 43210, USA
    Blood 119:6025-31. 2012

Detail Information

Publications28

  1. ncbi request reprint Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction
    Steven M Devine
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 112:990-8. 2008
    ..This trial was registered as no. NCT00241358 at www.ClinicalTrials.gov...
  2. pmc Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network prot
    Steven M Devine
    Medicine Department of Ohio State University, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 17:1343-51. 2011
    ..HCT after myeloablative chemoradiotherapy can be performed in a multicenter setting using a uniform method of TCD, resulting in a low risk of extensive chronic GVHD and relapse for patients with AML in CR1...
  3. pmc Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
    Mehdi Hamadani
    Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:547-53. 2009
    ..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy...
  4. pmc Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009
    ....
  5. ncbi request reprint Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
    Leuk Lymphoma 49:1893-8. 2008
    ..Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates...
  6. pmc Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma
    Neil C Dunavin
    Department of Internal Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Leuk Lymphoma 54:1658-64. 2013
    ..037). No superiority of one agent was seen. In summary, early or late ASCT is a viable option for patients with MM receiving induction treatment with novel targeted therapies...
  7. pmc Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 51:243-51. 2010
    ..Our data extrapolate on prior work and expand on ongoing controversies about optimal induction regimens for patients with MM planned for subsequent HDC/SCT and optimal sequencing of therapies...
  8. doi request reprint High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma
    Mehdi Hamadani
    Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Eur J Haematol 81:425-31. 2008
    ..At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively...
  9. pmc Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma
    Jarrod T Bruce
    Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University Medical Center, Columbus, OH, USA
    Clin Lymphoma Myeloma Leuk 12:325-9. 2012
    ..It also suggests that routine pulmonary function testing may be required in patients receiving these medications until larger studies can be performed to confirm this observation...
  10. pmc Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, B310 Starling Loving Hall, Columbus, OH 43210, USA
    Blood 119:6025-31. 2012
    ..This study demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML and identifies FLT3 as a novel pharmacodynamic end point for future trials...
  11. pmc Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 150:189-95. 2010
    ..In conclusion, dose-limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re-expression in CLL and NHL...
  12. pmc Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease
    Ming J Poi
    Department of Pharmacy, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, OH, USA
    Clin Pharmacokinet 52:705-12. 2013
    ..This phase II study (NCT00201786) was conducted to assess pentostatin efficacy and infectious complications seen from our previous phase I study in steroid-refractory acute GVHD (aGVHD)...
  13. ncbi request reprint Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
    Jonathon B Cohen
    Division of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio
    Cancer 120:1677-85. 2014
    ..In this study, the authors reviewed the outcomes of patients with myc-positive and double-hit NHL at The Ohio State University...
  14. pmc Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology and Oncology and the Comprehensive Cancer Center, Department of Medicine, The Ohio State University, B310 Starling Loving Hall, 320 West 10 Avenue, Columbus, OH 43210, USA
    Haematologica 95:1098-105. 2010
    ....
  15. pmc Dose escalation of lenalidomide in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 28:4919-25. 2010
    ..Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia...
  16. pmc The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    Don M Benson
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
    Blood 116:2286-94. 2010
    ..A phase 2 clinical trial of CT-011 in combination with lenalidomide for patients with MM should be considered...
  17. pmc Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia
    Samantha M Jaglowski
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    Br J Haematol 159:82-7. 2012
    ..In patients with high-risk interphase cytogenetics, CK remained predictive of worse OS (P = 0·02) and EFS (P = 0·009). These findings support further evaluation of metaphase karyotype in transplant risk assessment...
  18. pmc FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome
    Shun He
    Division of Hematology, Department of Internal Medicine, College of Medicine, Ohio State University, Columbus, Ohio The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Biol Blood Marrow Transplant 20:309-13. 2014
    ..Collectively, FP represents a promising novel and potent mobilization regimen with potential clinical application in both the autologous and allogeneic transplantation settings. ..
  19. pmc MicroRNAs activate natural killer cells through Toll-like receptor signaling
    Shun He
    Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 121:4663-71. 2013
    ..This may be important in the normal host defense against infection and/or malignant transformation...
  20. pmc Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:349-56. 2009
    ..Clofarabine exhibits evidence of single agent activity in relapsed or refractory DLBCL. However, further study with novel administration schedules that maintain this efficacy and limit toxicity is warranted...
  21. ncbi request reprint Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  22. pmc Pulmonary rehabilitation for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation
    Jerry Tran
    Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Medical Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 18:1250-4. 2012
    ..This may be an important adjunctive therapy for a debilitating disease with limited treatment options...
  23. pmc Regulation of acute graft-versus-host disease by microRNA-155
    Parvathi Ranganathan
    Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, Ohio State University, 460 West 12th Ave, Columbus, OH 43210, USA
    Blood 119:4786-97. 2012
    ..Altogether, our data indicate a role for miR-155 in the regulation of GVHD and point to miR-155 as a novel target for therapeutic intervention in this disease...
  24. ncbi request reprint Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients
    Hillard M Lazarus
    Department of Medicine, The University Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
    Biol Blood Marrow Transplant 11:389-98. 2005
    ..The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials...
  25. pmc Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    William Blum
    Division of Hematology and Oncology, Department of Medicine, and Center for Biostatistics, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:7473-8. 2010
    ..Levels of miR-29b should be validated as a predictive factor for stratification of older AML patients to decitabine treatment...
  26. ncbi request reprint Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
    Mehdi Hamadani
    Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 14:783-9. 2008
    ..The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections...
  27. ncbi request reprint Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor
    Beth Christian
    Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 28:e629-32. 2010
  28. ncbi request reprint Graft-versus-host disease: why have we not made more progress?
    Samantha M Jaglowski
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Curr Opin Hematol 21:141-7. 2014
    ..This potentially fatal complication occurs in approximately 50% of allo-SCT recipients...